{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:38Z","timestamp":1787064638833,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib\u2010based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients. Most common options are CyBorD (cyclophosphamide, bortezomib and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone). Main goal of our retrospective, multicentric study was to compare very good partial response rate (VGPR) or better after induction treatment in a real\u2010world setting in Argentina. Secondary objectives included comparison of complete response (CR) post\u2010induction and after bone marrow transplantation, grade 3\u20104 adverse events (AEs), progression\u2010free survival (PFS) and overall survival (OS). Three hundred twenty\u2010two patients were included (median age at diagnosis: 57\u2009years; 52% male; 28% had ISS3; 14% with high\u2010risk cytogenetics; median follow up: 34\u2009months). CyBorD was indicated in 74% and 26% received VTD. In VTD arm, 72.62% of patients achieved at least VGPR vs 53.36% receiving CyBorD (odds ratio, OR: 1.96 [95% confidence interval, CI: 1.08\u20103.57;\n                    <jats:italic>P<\/jats:italic>\n                    = .026] after adjusting by age, ISS [International Staging System], lactate dehydrogenase levels (LDH) and cytogenetic risk. Difference in VGPR was 19.26% (95% CI: 15\u201024). CR rate were 35.92% (VTD) vs 22.55% (CyBorD) (adjusted OR: 2.13 [95% CI: 1.12\u20104.05]). Difference in CR was 13.37% (95% CI: 9.6\u201017.53). Adverse events (AEs) were more common with VTD (69.05% vs 55.46% for CyBorD;\n                    <jats:italic>P<\/jats:italic>\n                    = .030), especially grade 3\u20104 neuropathy (\n                    <jats:italic>P<\/jats:italic>\n                    = .005) and thrombosis (\n                    <jats:italic>P<\/jats:italic>\n                    = .001). Thromboprophylaxis was inadequate in 20.24% of patients. Hematological AEs were more common with CyBorD, especially thrombocytopenia (\n                    <jats:italic>P<\/jats:italic>\n                    = .017). PFS and OS at 24\u2009months were not different between treatments. In this real\u2010world setting, VTD was associated with better CR and VGPR than CyBorD. Nevertheless, CyBorD continues to be the preferred induction regimen in Argentina, based on safety profile. Frontline autologous stem cell transplantation improves quality of responses, especially in countries with limited access to new drugs.\n                  <\/jats:p>","DOI":"10.1002\/hon.2729","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T10:24:03Z","timestamp":1584699843000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real world outcomes with\n                    <scp>Bortezomib Thalidomide dexamethasone<\/scp>\n                    and\n                    <scp>Cyclophosphamide Bortezomib dexamethasone<\/scp>\n                    induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma M\u00faltiple"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-7186","authenticated-orcid":false,"given":"Natalia P.","family":"Sch\u00fctz","sequence":"first","affiliation":[{"name":"Hospital Italiano de Buenos Aires \u2013 Servicio de Cl\u00ednica M\u00e9dica (Secci\u00f3n Hematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Instituto Alexander Fleming \u2013 Departamento de Hematolog\u00eda  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Duarte","sequence":"additional","affiliation":[{"name":"CEMIC \u2013 Secci\u00f3n Hematolog\u00eda  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Remaggi","sequence":"additional","affiliation":[{"name":"FUNDALEU \u2013 Departamento de Trasplante de M\u00e9dula \u00f3sea  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Yantorno","sequence":"additional","affiliation":[{"name":"Hospital Italiano de La Plata \u2013 Servicio de Hematolog\u00eda (Unidad de Trasplante de M\u00e9dula \u00f3sea)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Corzo","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas \u201cJos\u00e9 de San Mart\u00edn\u201d \u2013 Departamento de Cl\u00ednica M\u00e9dica (Divisi\u00f3n Hematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Zabaljauregui","sequence":"additional","affiliation":[{"name":"Academia Nacional de Medicina \u2013 Departamento de Hemato\u2010Oncolog\u00eda (Divisi\u00f3n Oncohematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Shanley","sequence":"additional","affiliation":[{"name":"Hospital Brit\u00e1nico \u2013 Departamento de Hematolog\u00eda (Unidad de Trasplante de M\u00e9dula \u00f3sea)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lopresti","sequence":"additional","affiliation":[{"name":"Hospital Posadas \u2013 Departamento de Medicina Interna  Mor\u00f3n Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Orlando","sequence":"additional","affiliation":[{"name":"Hospital Rodolfo Rossi \u2013 Departamento de Hematolog\u00eda y Trasplante de M\u00e9dula \u00f3sea  La Plata Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Verri","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones M\u00e9dicas \u201cAlfredo Lanari\u201d UBA \u2013 Departamento de Hematolog\u00eda  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Quiroga","sequence":"additional","affiliation":[{"name":"Complejo M\u00e9dico de la Polic\u00eda Federal Argentina Churruca Visca \u2013 Departamento de Cl\u00ednica M\u00e9dica (Secci\u00f3n Hematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Cl\u00ednica 25 de Mayo  Mar del Plata Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Sanatorio Dr. Julio M\u00e9ndez \u2013 Departamento de Cl\u00ednica M\u00e9dica (Secci\u00f3n Hematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorotea","family":"Fantl","sequence":"additional","affiliation":[{"name":"Hospital Italiano de Buenos Aires \u2013 Servicio de Cl\u00ednica M\u00e9dica (Secci\u00f3n Hematolog\u00eda)  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S160029"},{"key":"e_1_2_7_5_1","unstructured":"United Nations Statistic Division.https:\/\/unstats.un.org\/unsd\/environment\/totalarea.htm. Accessed November 11 2019."},{"key":"e_1_2_7_6_1","unstructured":"United Nations Population Division.https:\/\/population.un.org\/wpp\/Publications\/Files\/WPP2017_Volume-II-Demographic-Profiles.pdf. Accessed November 12 2019."},{"key":"e_1_2_7_7_1","unstructured":"Sociedad Argentina de Hematolog\u00eda. Gu\u00edas de Diagn\u00f3stico y Tratamiento. Gammapat\u00edas monoclonales.2017.http:\/\/sah.org.ar\/docs\/2017\/002-Gammapat%C3%ADas%20Monoclonales.pdf. Accessed November 13 2019."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13483"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.021"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718761776"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13357"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.140"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23835"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:17:18Z","timestamp":1693808238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/hon.2729"],"URL":"https:\/\/doi.org\/10.1002\/hon.2729","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"2019-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}